Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

Category list : Medicines and Healthcare products Regulatory Agency (MHRA)

Sort by: Newest first Oldest first A-Z Z-A

  • Bottle of pills with the word ALERT! superimposed on top

    MHRA correction for Abraxane drug recall Subscription

    9 NOV 2009 10:30

    The wrong batch of Abraxane (paclitaxel albumin; Abraxis) powder for suspension for infusion, 5mg/ml in single 50ml vials, was named for recall in an alert issued last Thursday (5 November 2009).

  • MHRA:?not here just to approve artwork Subscription

    23 MAY 2012

    From Miss J. MacDonald, MRPharmSIn response to the letter from J. Paul Smith to the PJ (12 May 2012, p589), I want to correct some factual inaccuracies.

  • ‘Debranding’ of branded products Subscription

    17 JUL 2015 11:05 By Mark Burdon

    For some years now, certain manufacturers have been removing the brand name of a medicine and relaunching the product as a generic — so called “debranding”. The aim of this exercise is to circumvent the Pharmaceutical Price Regulation Scheme (PPRS) and allow the manufacturer to increase the price to the NHS.

  • The worst outbreak of the fatal haemorrhagic Ebola virus disease started in the West African country Guinea, infected 17,942 individuals and killed 6,388 people as of 16 December

    2014: The Pharmaceutical Journal's news in review Subscription

    18 DEC 2014

    Looking back at some of the biggest news stories from the past year. 

  • Newborn baby

    Adverse drug reactions underreported in children aged under two years

    12 SEP 2016 16:53 By Emma Wilkinson

    Researchers have questioned the effectiveness of the MHRA’s Yellow Card scheme after receiving a low number of reports involving infants aged under two years.

  • Non-small cell lung carcinoma NSCLC

    Alectinib reduces CNS progression in NSCLC

    8 SEP 2017 14:43

    Data from two clinical trials have shown that second-generation ALK inhibitor alectinib (Alecensa, Roche) reduces central nervous system progression in ALK-positive non-small cell lung carcinoma.

  • Matt Hancock

    All opioid medicines to contain clear warnings about addiction, health secretary announces

    29 APR 2019 16:16 By Julia Robinson

    All opioid medicines will need to carry prominent warnings about the risk of addiction, health and social care secretary, Matt Hancock, has announced.

  • Amoxicillin drug alert Subscription

    25 JUL 2014 17:52

    A class 2 drug alert has been issued for three batches of amoxicillin sodium 500mg powder for solution for injection from Wockhardt: 1WA4002, 1WA4003, 1WA4004. This is further to the class 4 drug alert issued last week due to additional reports of injection site reactions ...

  • Amoxicillin in infants drug alert Subscription

    18 JUL 2014 0:00

    A class four drug alert, caution in use, has been issued for amoxicillin sodium 250mg, 500mg and 1mg powder for solution for injection from Wockhardt. This is due to a number of reports of extravasation and injection site reactions in infants less than one year old and the medicine should not be used in these patients.

  • Diagnosing epilepsy in children and strategies for the selection of appropriate drug treatments. In the image, a 9-year old girl in a magnetoencephalograph (MEG) scanner, which is used to detect neurological disorders such as epilepsy

    Antiepileptic drug treatment in children Subscription

    2 DEC 2015 14:03 By Richard Appleton

    Diagnosing epilepsy in children and strategies for selecting appropriate drug treatments.

Show  10 per page20 per page50 per page

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.